NCT05094804 2023-11-02A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsOncoResponse, Inc.Phase 1/2 Unknown172 enrolled
NCT00413075 2015-07-08Study of Oral PXD101 in Patients With Advanced Solid Tumors or LymphomaValerio TherapeuticsPhase 1 Completed121 enrolled
NCT00413322 2015-07-08Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsValerio TherapeuticsPhase 1 Completed35 enrolled